How are monoclonal antibodies changing the treatment paradigm for myeloma?

Published on

At the 20th Congress of the European Hematology Association (EHA), Prof Sagar Lonial, Professor and Executive Vice Chair in the Department of Hematology and Medical Oncology, and Professor and Chief Medical Officer at the Winship Cancer Institute of Emory University, explains how monoclonal antibodies are likely to play a key role in the progress of treating myeloma. There are several promising monoclonal antibodies that are in clinical development and may be used to treat patients as front-line or relapsed/refractory therapies.

View more programs featuring

Page last updated on January 26, 2016